ProCE Banner Activity

IMpower010 Subgroup Analysis: Outcomes by Therapy Prior to Adjuvant Atezolizumab in Patients With Resected Stage IB-IIIA NSCLC

Slideset Download
Conference Coverage
DFS benefit with adjuvant atezolizumab vs best supportive care was seen across most disease stages and prior treatments.

Released: September 15, 2021

Expiration: September 14, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme